背景:血管内皮生长因子(VEGF)与异常眼底新生血管形成有关。因此,抗VEGF剂对于眼科治疗至关重要。本文综述了近二十年来抗VEGF药物在眼科中的应用,旨在为进一步的研究提供见解。
方法:从2003年到2023年,在WebofScienceCoreCollection文献中采用了细致的搜索策略来收集相关文献,然后用VOSviewer分析,CiteSpace,和R包Bibliometrix。
结果:该研究包括来自83个国家和3,445个机构的3,602份出版物。就出版物数量而言,美国和中国已成为主要贡献者。约翰霍普金斯大学,悉尼大学,和GenentechInc被确定为该领域的领先者。“视网膜”的发行量最高,而“眼科”的引用频率最高。在15918名学者中,BresslerNM,HolzFG,GlassmanAR,和BandelloF在出版物上领先,而布朗DM是被引用最多的作者。高频关键词包括“内皮生长因子,\"\"治疗,\"\"安全,“和”随机临床试验。
结论:抗VEGF药物在治疗新生血管性眼病方面取得了显著的成功,尤其是湿性年龄相关性黄斑变性和糖尿病性黄斑水肿,注重临床疗效,注射方案,和安全。未来的方向包括开发新的抗VEGF药物,药物输送系统,非侵入性管理,多靶点药物,利用大数据和人工智能,并解决当前的治疗限制。该领域的不断创新和方法改进有望取得更多突破,提供有效的,安全,和眼病治疗的经济选择。
BACKGROUND: Vascular Endothelial Growth Factor (VEGF) is associated with abnormal fundus
neovascularization. Consequently, Anti-VEGF agents are vital for ophthalmic treatment. This paper reviews the application of anti-VEGF agents in ophthalmology over the past two decades with the aim of providing insights for further research.
METHODS: A meticulous search strategy was employed in the Web of Science Core Collection literature from 2003 to 2023 to gather relevant literature, which was then analyzed using VOSviewer, CiteSpace, and the R package Bibliometrix.
RESULTS: The study included 3,602 publications from 83 countries and 3,445 institutions. The United States and China have emerged as leading contributors in terms of the publication volume. Johns Hopkins University, the University of Sydney, and Genentech Inc were identified as frontrunners in this field. \"Retina\" had the highest publication volume, whereas \"Ophthalmology\" had the highest citation frequency. Among the 15,918 scholars, Bressler NM, Holz FG, Glassman AR, and Bandello F led in publication volume, while Brown DM was the most cited author. High-frequency keywords included \"Endothelial Growth Factor,\" \"Therapy,\" \"Safety,\" and \"Randomized Clinical Trial.\"
CONCLUSIONS: Anti-VEGF drugs have shown notable success in treating neovascular eye diseases, especially wet age-related macular degeneration and diabetic macular edema, focusing on clinical efficacy, injection regimens, and safety. Future directions include developing new anti-VEGF drugs, drug delivery systems, non-invasive administration, multi-target drugs, leveraging big data and artificial intelligence, and addressing the current treatment limits. Continuous innovation and method improvement in this field promise more breakthroughs, providing effective, safe, and economical options for eye disease treatment.